U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Bile Duct Carcinoma

MedGen UID:
1652770
•Concept ID:
C4727192
•
Neoplastic Process

Definition

Bile duct carcinoma that is resistant to treatment. [from NCI]

Professional guidelines

PubMed

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ
Nat Rev Gastroenterol Hepatol 2020 Sep;17(9):557-588. Epub 2020 Jun 30 doi: 10.1038/s41575-020-0310-z. PMID: 32606456Free PMC Article
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D
Nat Rev Gastroenterol Hepatol 2016 May;13(5):261-80. Epub 2016 Apr 20 doi: 10.1038/nrgastro.2016.51. PMID: 27095655

Recent clinical studies

Etiology

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
Gandhy SU, Casak SJ, Mushti SL, Cheng J, Subramaniam S, Zhao H, Zhao M, Bi Y, Liu G, Fan J, Adeniyi O, Charlab R, Kufrin D, Thompson MD, Jarrell K, Auth D, Lemery SJ, Pazdur R, Kluetz PG, Fashoyin-Aje LA
Clin Cancer Res 2023 Oct 13;29(20):4027-4031. doi: 10.1158/1078-0432.CCR-23-1042. PMID: 37289037Free PMC Article
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group
Lancet Oncol 2023 Jul;24(7):772-782. Epub 2023 Jun 2 doi: 10.1016/S1470-2045(23)00242-5. PMID: 37276871
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Kehmann L, Berres ML, Gonzalez-Carmona M, Modest DP, Mohr R, Wree A, Venerito M, Strassburg C, Keitel V, Trautwein C, Luedde T, Roderburg C
BMC Cancer 2023 May 22;23(1):470. doi: 10.1186/s12885-023-10972-6. PMID: 37217885Free PMC Article
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX
Lancet Oncol 2020 Jun;21(6):796-807. Epub 2020 May 13 doi: 10.1016/S1470-2045(20)30157-1. PMID: 32416072Free PMC Article
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D
Nat Rev Gastroenterol Hepatol 2016 May;13(5):261-80. Epub 2016 Apr 20 doi: 10.1038/nrgastro.2016.51. PMID: 27095655

Diagnosis

Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH, Tan E, Kim R
Expert Opin Investig Drugs 2021 Apr;30(4):333-341. Epub 2020 Dec 30 doi: 10.1080/13543784.2021.1867537. PMID: 33378249
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ
Nat Rev Gastroenterol Hepatol 2020 Sep;17(9):557-588. Epub 2020 Jun 30 doi: 10.1038/s41575-020-0310-z. PMID: 32606456Free PMC Article
Applied precision cancer medicine in metastatic biliary tract cancer.
Taghizadeh H, Müllauer L, Mader R, Prager GW
Hepatol Int 2020 Mar;14(2):288-295. Epub 2020 Feb 25 doi: 10.1007/s12072-020-10020-6. PMID: 32100259Free PMC Article
Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
Mizutani S, Kuroda J, Sasaki N, Kiyota M, Tatekawa S, Tsukamoto T, Maegawa S, Chinen Y, Shimura Y, Nagoshi H, Kobayashi T, Horiike S, Tando S, Fushiki S, Taniwaki M
Intern Med 2016;55(9):1183-6. Epub 2016 May 1 doi: 10.2169/internalmedicine.55.5319. PMID: 27150876
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D
Nat Rev Gastroenterol Hepatol 2016 May;13(5):261-80. Epub 2016 Apr 20 doi: 10.1038/nrgastro.2016.51. PMID: 27095655

Therapy

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.
Sahin IH, Tan E, Kim R
Expert Opin Investig Drugs 2021 Apr;30(4):333-341. Epub 2020 Dec 30 doi: 10.1080/13543784.2021.1867537. PMID: 33378249
Cholangiocarcinoma: investigations into pathway-targeted therapies.
Ntanasis-Stathopoulos I, Tsilimigras DI, Gavriatopoulou M, Schizas D, Pawlik TM
Expert Rev Anticancer Ther 2020 Sep;20(9):765-773. Epub 2020 Aug 16 doi: 10.1080/14737140.2020.1807333. PMID: 32757962
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX
Lancet Oncol 2020 Jun;21(6):796-807. Epub 2020 May 13 doi: 10.1016/S1470-2045(20)30157-1. PMID: 32416072Free PMC Article
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D
Nat Rev Gastroenterol Hepatol 2016 May;13(5):261-80. Epub 2016 Apr 20 doi: 10.1038/nrgastro.2016.51. PMID: 27095655

Prognosis

Assessing the incidence of complications and malignancies in the long-term management of benign biliary strictures with a percutaneous transhepatic drain.
Yoshitomi M, Kawahara R, Taniwaki S, Midorikawa R, Kojima S, Muroya D, Arai S, Shirahama T, Kanno H, Fukutomi S, Goto Y, Nomura Y, Akashi M, Sato T, Sakai H, Hisaka T, Akagi Y
Medicine (Baltimore) 2022 Mar 11;101(10):e29048. doi: 10.1097/MD.0000000000029048. PMID: 35451417Free PMC Article
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
Rizzo A, Ricci AD, Brandi G
Expert Opin Investig Drugs 2021 Apr;30(4):317-324. Epub 2020 Oct 25 doi: 10.1080/13543784.2021.1837774. PMID: 33054456
Applied precision cancer medicine in metastatic biliary tract cancer.
Taghizadeh H, Müllauer L, Mader R, Prager GW
Hepatol Int 2020 Mar;14(2):288-295. Epub 2020 Feb 25 doi: 10.1007/s12072-020-10020-6. PMID: 32100259Free PMC Article
Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.
Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, Yoshikawa N, Furukawa R, Saito H
Cell Rep 2019 Apr 23;27(4):1265-1276.e4. doi: 10.1016/j.celrep.2019.03.088. PMID: 31018139
In vitro and in vivo antitumor activity of tiliacorinine in human cholangiocarcinoma.
Janeklang S, Nakaew A, Vaeteewoottacharn K, Seubwai W, Boonsiri P, Kismali G, Suksamrarn A, Okada S, Wongkham S
Asian Pac J Cancer Prev 2014;15(17):7473-8. doi: 10.7314/apjcp.2014.15.17.7473. PMID: 25227861

Clinical prediction guides

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC
J Hepatol 2023 Dec;79(6):1450-1458. Epub 2023 Aug 28 doi: 10.1016/j.jhep.2023.08.017. PMID: 37647991
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group
Lancet Oncol 2023 Jul;24(7):772-782. Epub 2023 Jun 2 doi: 10.1016/S1470-2045(23)00242-5. PMID: 37276871
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX
Lancet Oncol 2020 Jun;21(6):796-807. Epub 2020 May 13 doi: 10.1016/S1470-2045(20)30157-1. PMID: 32416072Free PMC Article
Applied precision cancer medicine in metastatic biliary tract cancer.
Taghizadeh H, Müllauer L, Mader R, Prager GW
Hepatol Int 2020 Mar;14(2):288-295. Epub 2020 Feb 25 doi: 10.1007/s12072-020-10020-6. PMID: 32100259Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...